From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis
Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Age | 1062 | Â | Â | Â | Â |
 <  = 60 | 590 | Reference |  |  |  |
 > 60 | 472 | 1.445 (0.941–2.219) | 0.093 | 1.280 (0.751–2.180) | 0.364 |
T stage | 1059 | Â | Â | Â | Â |
T1 | 274 | Reference | Â | Â | Â |
T2&T3&T4 | 785 | 1.781 (1.033–3.071) | 0.038 | 1.271 (0.525–3.080) | 0.595 |
N stage | 1044 | Â | Â | Â | Â |
N0 | 511 | Reference | Â | Â | Â |
N1&N2&N3 | 533 | 3.797 (2.222–6.489) |  < 0.001 | 2.840 (1.451–5.559) | 0.002 |
M stage | 903 | Â | Â | Â | Â |
M0 | 884 | Reference | Â | Â | Â |
M1 | 19 | 7.454 (3.988–13.931) |  < 0.001 | 6.663 (3.139–14.142) |  < 0.001 |
Pathologic stage | 1041 | Â | Â | Â | Â |
Stage I | 178 | Reference | Â | Â | Â |
Stage II&Stage III&Stage IV | 863 | 3.396 (1.478–7.803) | 0.004 | 1.118 (0.300–4.165) | 0.869 |
ER status | 1013 | Â | Â | Â | Â |
Negative | 232 | Reference | Â | Â | Â |
Positive | 781 | 0.559 (0.351–0.891) | 0.015 | 0.435 (0.193–0.978) | 0.044 |
PR status | 1010 | Â | Â | Â | Â |
Negative | 334 | Reference | Â | Â | Â |
Positive | 676 | 0.519 (0.334–0.807) | 0.004 | 0.707 (0.321–1.555) | 0.388 |
HER2 status | 704 | Â | Â | Â | Â |
Negative | 550 | Reference | Â | Â | Â |
Positive | 154 | 1.477 (0.740–2.948) | 0.269 |  |  |
radiation_therapy | 977 | Â | Â | Â | Â |
No | 430 | Reference | Â | Â | Â |
Yes | 547 | 0.791 (0.483–1.295) | 0.351 |  |  |
HSPB1 | 1062 | Â | Â | Â | Â |
Low | 528 | Reference | Â | Â | Â |
High | 534 | 1.515 (1.239–1.837) | 0.029 |  |  |